One week's treatment with NN2211, a long-acting GLP-1 derivative, markedly ameliorates 24-h glycemia and β-cell function and reduces fasting endogenous glucose release in type 2 diabetic patients

被引：0
|
作者：
Degn, K
Juhl, C
Sturis, J
Jackobsen, G
Chandramouli, V
Rungby, J
机构：
来源：
DIABETES | 2003年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A116 / A116
页数：1
相关论文
共 19 条
  • [1] One week's treatment with NN2211, a long-acting GLP-1 derivative, significantly improves first phase insulin response and other markers of β-cell function, reduces endogenous glucose release, and ameliorates 24-h glycemia in Type 2 diabetic patients.
    Degn, KB
    Juhl, CB
    Sturis, J
    Jakobsen, G
    Chandramouli, V
    Rungby, J
    Landau, BR
    Schmitz, OE
    DIABETOLOGIA, 2003, 46 : A285 - A285
  • [2] One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes
    Degn, KB
    Juhl, CB
    Sturis, J
    Jakobsen, G
    Brock, B
    Chandramouli, V
    Rungby, J
    Landau, BR
    Schmitz, O
    DIABETES, 2004, 53 (05) : 1187 - 1194
  • [3] The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice
    Rolin, B
    Larsen, MO
    Gotfredsen, CF
    Deacon, CF
    Carr, RD
    Wilken, M
    Knudsen, LB
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2002, 283 (04): : E745 - E752
  • [4] Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes
    Juhl, CB
    Hollingdal, M
    Sturis, J
    Jakobsen, G
    Agerso, H
    Veldhuis, J
    Porksen, N
    Schmitz, O
    DIABETES, 2002, 51 (02) : 424 - 429
  • [5] The long-acting GLP-1 derivative, NN2211, a new agent for the treatment of Type 2 diabetes
    Matthews, D
    Madsbad, S
    Schmitz, O
    Langendorf, KW
    Jakobsen, G
    DIABETES, 2002, 51 : A84 - A84
  • [6] A long-acting GLP-1 derivative, NN2211: its use in the treatment of Type 2 diabetes
    Matthews, DR
    Madsbad, S
    Schmitz, O
    Langendorf, KW
    Jakobsen, G
    DIABETOLOGIA, 2002, 45 : A217 - A218
  • [7] The long-acting GLP-1 derivative, NN2211, restores beta cell sensitivity to glucose in subjects with type 2 diabetes
    Chang, A
    Jakobsen, G
    Sturis, J
    An, B
    Smith, M
    Bloem, C
    Galecki, A
    Halter, J
    DIABETES, 2003, 52 : A113 - A113
  • [8] Evidence of a substantial reduction in fasting and postprandial glycemia in type 2 diabetes after bedtime administration of a long-acting GLP-1 derivative, NN2211
    Juhl, CB
    Hollingdal, M
    Porksen, N
    Sturis, J
    Jakobsen, G
    Schmitz, O
    DIABETES, 2001, 50 : A118 - A118
  • [9] Long-acting GLP-1 derivative NN2211 markedly attenuates diabetes development in the male Zucker Diabetic Fatty rat
    Sturis, J
    Jappe, MB
    Knudsen, LB
    Wilken, M
    Gjedsted, A
    Primdahl, S
    Gotfredsen, CF
    DIABETOLOGIA, 2000, 43 : A145 - A145
  • [10] The long-acting GLP-1 derivative NN2211 markedly slows the development of diabetes in the male Zucker diabetic fatty rat
    Sturis, J
    Jappe, MB
    Knudsen, LB
    Wilken, M
    Gjedst-Ed, A
    Primdahl, S
    Gotfredsen, CF
    DIABETES, 2000, 49 : A228 - A228
12